Video Summary
In this discussion, Roger Thorpe and Alison Brown from Thorpe Benefits explored the evolving role of Ozempic and similar medications in employer-sponsored health plans. They discussed how Ozempic, originally a diabetes medication, is now being considered for weight loss treatment through drugs like Wogovie. Alison noted that while Ozempic works for many people with diabetes, its long-term effects are still uncertain. Roger highlighted the significant cost implications, with monthly costs ranging from $300 to $500. They emphasized the importance of viewing obesity as a disease rather than a lifestyle choice, and discussed the need for employers to consider covering weight loss medications while being aware of the potential long-term costs. The conversation also covered the importance of integrating medication treatment with lifestyle changes and creating a culture of health within organizations. They concluded that employers need to proactively address these issues as weight loss medications become more prevalent in drug formularies.
Chapters
Introduction to Ozempic and Wogovie in Employer Health Plans
Roger Thorpe introduced the topic, explaining how Ozempic, originally for diabetes, is now being considered for weight loss treatment. Alison Brown noted that Wogovie has been approved specifically for weight loss and is now available through prior authorization processes.
Effectiveness and Impact of Ozempic
Alison discussed how Ozempic is effective for many people with diabetes, with weight loss as a side effect. Roger mentioned the varying opinions on its effectiveness, describing it as potentially a ‘game changer’ while noting the need for cost-benefit analysis from an employer perspective.
Cost Implications of Ozempic and Wogovie
Alison highlighted the significant cost implications, with monthly costs around $300, and discussed how this could impact larger employers with many employees on the medication. Roger emphasized the importance of considering long-term cost commitments.
Obesity as a Disease vs. Lifestyle Choice
Roger and Alison discussed the importance of recognizing obesity as a disease rather than a lifestyle choice, comparing it to historical biases around mental health treatment. They emphasized the need for proper definitions and prior authorization parameters.
Integration of Medication and Lifestyle Changes
Roger discussed the importance of combining medication treatment with lifestyle changes, including exercise and dietary adjustments. Alison noted that the drugs can decrease muscle mass, highlighting the need for comprehensive medical guidance.
Creating a Culture of Health in Organizations
Roger emphasized the importance of supporting health education and creating a culture of health within organizations, noting that medication is just one part of the solution.
Conclusion and Next Steps
Roger and Alison concluded that employers need to review their formularies and make proactive decisions about covering weight loss medications, emphasizing the urgency of these discussions.